351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

• Makoto Tahara,
• Kevin Harrington,
• Ezra Cohen,
• Barbara Burtness,
• Quynh-Thu Le,
• Lisa Licitra,
• Jean-Pascal Machiels,
• Lilian Siu,
• Danny Rischin,
• Jan Vermorken,
• Natalyn Hawk,
• Joy Ge,
• Behzad Bidadi,
• Ramona Swaby

Affiliations

Makoto Tahara

8National Cancer Center Hospital, Kashiwa, Japan

Kevin Harrington

Aff11 grid.18886.3f0000000112714623The Institute of Cancer Research/The Royal Marsden Hospital London UK

Ezra Cohen

Aff2 grid.420234.3UC San Diego Health System - La Jolla La Jolla Ca USA

Barbara Burtness

Aff3 0000000419368710grid.47100.32Yale School of Medicine and Yale Cancer Center New Haven CT USA

Quynh-Thu Le

Aff6 0000000419368956grid.168010.eStanford University Stanford CA USA

Lisa Licitra

Aff9 0000 0001 0807 2568grid.417893.0Fondazione IRCCS Istituto Nazionale dei Tumori Milan and University of Milan Milan Italy

Jean-Pascal Machiels

Aff1 0000 0001 2294 713Xgrid.7942.8Department of Medical OncologyInstitut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain Brussels Belgium

Lilian Siu

2Princess Margaret Cancer Centre, Toronto, Canada

Danny Rischin

1 Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Jan Vermorken

6Antwerp University Hospital, Edegem, Belgium

Natalyn Hawk

10Eisai Inc., Woodcliff Lake, NJ, USA

Joy Ge

11Merck and Co., Inc., Kenilworth, NJ, USA

Behzad Bidadi

11Merck and Co., Inc., Kenilworth, NJ, USA

Ramona Swaby

11Merck and Co., Inc., Kenilworth, NJ, USA